Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Messina

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 16, 2019
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapyGiuseppe Badalamenti, Lorena Incorvaia, Carlo Messina, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 6, 2026
Stereotactic body radiotherapy for non-spinal bone oligometastases: a mono-institutional experienceFrancesco Cuccia, Gianluca Mortellaro, Marina Campione, et al.
Nuclear Medicine Communications|June 5, 2024
Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practicePierpaolo Alongi, Marco Messina, Alessio Pepe, et al.
Therapeutic Advances in Medical Oncology|February 1, 2018
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomesAlessia Cavo, Alessandra Rubagotti, Elisa Zanardi, et al.
Cancers|September 9, 2023
Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE AnalysisAndrés J M Ferreri, Pier Luigi Zinzani, Carlo Messina, et al.
Journal of Personalized Medicine|July 25, 2025
Stereotactic Body Radiotherapy for the Treatment of Oligometastases Located in the Peritoneum or in the Abdominal Wall: Preliminary Results from a Mono-Institutional AnalysisFrancesco Cuccia, Salvatore D'Alessandro, Marina Campione, et al.
BJU International|January 4, 2012
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatmentAndrea Mancuso, Eugenio Donato Di Paola, Alvaro Leone, et al.
Frontiers in Surgery|May 23, 2022
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic CancerValeria Merz, Domenico Mangiameli, Camilla Zecchetto, et al.
American Journal of Hematology|March 2, 2016
Elderly patients > 65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programsMassimo Bernardi, Matteo Carrabba, Carlo Messina, et al.
Oncoimmunology|November 12, 2020
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisionsLorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 16, 2019
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapyGiuseppe Badalamenti, Lorena Incorvaia, Carlo Messina, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 6, 2026
Stereotactic body radiotherapy for non-spinal bone oligometastases: a mono-institutional experienceFrancesco Cuccia, Gianluca Mortellaro, Marina Campione, et al.
Nuclear Medicine Communications|June 5, 2024
Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practicePierpaolo Alongi, Marco Messina, Alessio Pepe, et al.
Therapeutic Advances in Medical Oncology|February 1, 2018
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomesAlessia Cavo, Alessandra Rubagotti, Elisa Zanardi, et al.
Cancers|September 9, 2023
Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE AnalysisAndrés J M Ferreri, Pier Luigi Zinzani, Carlo Messina, et al.
Journal of Personalized Medicine|July 25, 2025
Stereotactic Body Radiotherapy for the Treatment of Oligometastases Located in the Peritoneum or in the Abdominal Wall: Preliminary Results from a Mono-Institutional AnalysisFrancesco Cuccia, Salvatore D'Alessandro, Marina Campione, et al.
BJU International|January 4, 2012
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatmentAndrea Mancuso, Eugenio Donato Di Paola, Alvaro Leone, et al.
Frontiers in Surgery|May 23, 2022
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic CancerValeria Merz, Domenico Mangiameli, Camilla Zecchetto, et al.
American Journal of Hematology|March 2, 2016
Elderly patients > 65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programsMassimo Bernardi, Matteo Carrabba, Carlo Messina, et al.
Oncoimmunology|November 12, 2020
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisionsLorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
Pageof 11